Jennifer L. Stevens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer L. Stevens has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Angela B. Mariotto
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
28 shared publications - Karen Mittu
Information Management Services Calverton Maryland USA
27 shared publications - Nadia Howlader
Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland USA
27 shared publications - Ron A. Dewar
Cancer Care Program, Nova Scotia Health Authority, Nova Scotia, Canada
27 shared publications - Theresa P. Devasia
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
27 shared publications Anca Preda
Division of Cancer Control and Population Science, National Cancer Institute , Rockville, MD
1 shared publication
Latest Publications
- 14 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1868-1874
Enrollment in Children’s Oncology Group’s clinical trials: population-based linkage with the National Childhood Cancer Registry
Background: Improvements in outcomes among children and adolescents diagnosed with cancer are attributable to many factors, including clinical trials such as those administered through the Children’s Oncology Group (COG) as well as population-based resources such as the National Childhood Cancer Registry (NCCR). The objective of this study was to link COG trial data with the NCCR to evaluate overall enrollment patterns. Methods: Data were received from the NCCR and COG that were linked using an array of variables, then compared to evaluate enrollment patterns in COG studies from 2007 to 2018. Multivariable logistic regression was used to identify characteristics associated with not being enrolled in a COG study. Results: Among 134 696 NCCR patients with cancer, 51 062 matched with COG study enrollees. There were several differences in demographic and clinical characteristics between individuals enrolled and not enrolled in COG studies. Enrollment was higher among children aged from birth to 4 years compared with adolescents aged 15-19 years (53.7% vs 20.1%). Differences by race and ethnicity were also observed; for example, individuals who identified as non-Hispanic White were more likely to be enrolled than were individuals who identified as non-Hispanic Asian or Pacific Islander (38.8% vs 32.9%). In a multivariable logistic regression model, several characteristics were strongly associated with not being enrolled in a COG study, including age at diagnosis, year of diagnosis, race and ethnicity, and cancer type. Conclusion: Our results suggest that several groups are underrepresented in COG clinical trials. This information can help guide the prioritization of population groups for engagement in future studies.
- 14 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1868-1874
Enrollment in Children’s Oncology Group’s clinical trials: population-based linkage with the National Childhood Cancer Registry
Background: Improvements in outcomes among children and adolescents diagnosed with cancer are attributable to many factors, including clinical trials such as those administered through the Children’s Oncology Group (COG) as well as population-based resources such as the National Childhood Cancer Registry (NCCR). The objective of this study was to link COG trial data with the NCCR to evaluate overall enrollment patterns. Methods: Data were received from the NCCR and COG that were linked using an array of variables, then compared to evaluate enrollment patterns in COG studies from 2007 to 2018. Multivariable logistic regression was used to identify characteristics associated with not being enrolled in a COG study. Results: Among 134 696 NCCR patients with cancer, 51 062 matched with COG study enrollees. There were several differences in demographic and clinical characteristics between individuals enrolled and not enrolled in COG studies. Enrollment was higher among children aged from birth to 4 years compared with adolescents aged 15-19 years (53.7% vs 20.1%). Differences by race and ethnicity were also observed; for example, individuals who identified as non-Hispanic White were more likely to be enrolled than were individuals who identified as non-Hispanic Asian or Pacific Islander (38.8% vs 32.9%). In a multivariable logistic regression model, several characteristics were strongly associated with not being enrolled in a COG study, including age at diagnosis, year of diagnosis, race and ethnicity, and cancer type. Conclusion: Our results suggest that several groups are underrepresented in COG clinical trials. This information can help guide the prioritization of population groups for engagement in future studies.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CML showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CML showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CRC showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for CRC showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary materials and methods outline SAS code used to fit flexible parametric survival model. Document includes a simple example along with a link to the Github repository containing full macro code and worked examples.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary materials and methods outline SAS code used to fit flexible parametric survival model. Document includes a simple example along with a link to the Github repository containing full macro code and worked examples.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing model fit criteria for final model for each cancer site.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing model fit criteria for final model for each cancer site.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Increase in the Life Expectancy of Patients with Cancer in the United States
Supplementary table containing sensitivity analysis results for males aged 55 at diagnosis.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for melanoma showing treatments that received FDA approval between 1975 and 2018.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for DLBCL showing treatments that received FDA approval between 1975 and 2018.
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Increase in the Life Expectancy of Patients with Cancer in the United States
Timeline of treatment advances for DLBCL showing treatments that received FDA approval between 1975 and 2018.